Market Overview

FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status in November Report - Bloomberg

Share:
Related AMRN
Benzinga's Top #PreMarket Losers
These 5 Stocks Have More Than Doubled In 2015
Matinas MAT9001 Beats Vascepa In Head-To-Head Trial (Seeking Alpha)

View Orange Book.

Posted-In: News FDA

 

Related Articles (AMRN)

Around the Web, We're Loving...